Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Narcolepsy
Interventions: Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 36
States / cities: Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more

Conditions: Alzheimer's Disease
Interventions: caprylic triglyceride, long-chain triglyceride; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 55 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more

Conditions: Spondyloarthropathies
Interventions: CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 32
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more

Conditions: Asthma
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more

Conditions: Alzheimer's Disease
Interventions: Aducanumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 1,027 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 130
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more

Conditions: Meningococcal Meningitis
Interventions: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine; Biological
Lead sponsor: Novartis; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 17
States / cities: Birmingham, Alabama • Fremont, California • Madera, California + 14 more

Conditions: Spinal Cord Injuries
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus, Type 1
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 34
States / cities: Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin, Pen auto-injector; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Rheumatoid Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 12
States / cities: Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 8 more

Conditions: Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions: mRNA COVID-19, IIV4, Placebo (saline); Biological · Other
Lead sponsor: Duke University; Other
Eligibility: 5 Years and older
Enrollment: 348 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio

Conditions: Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
Interventions: Vupanorsen, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 59
States / cities: Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more

Conditions: Pain
Interventions: Bupivacaine, Saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ANCA-Associated Vasculitis
Interventions: Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine; Drug · Biological
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 41
States / cities: Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more

Conditions: Lupus Nephritis
Interventions: Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • San Bernardino, California • Sylmar, California + 13 more

Conditions: Healthy
Interventions: ExPEC4V, Placebo; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Wichita, Kansas • Knoxville, Tennessee

Conditions: Acute Kidney Injury
Interventions: Saline, Sodium Nitrite; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Obesity, Insulin Resistance
Interventions: MICARDIS® (telmisartan); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Westlake Village, California + 5 more

Conditions: Digestive Disease, Gut Health
Interventions: Probiotic, Placebo; Dietary Supplement · Other
Lead sponsor: Synbiotic Health; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Colitis, Ulcerative
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 32
States / cities: Litchfield Park, Arizona • Apple Valley, California • Lancaster, California + 26 more

Conditions: COVID-19
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more

Conditions: Colitis, Ulcerative
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more

Conditions: Acne Vulgaris
Interventions: Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan); Drug · Other
Lead sponsor: Seegpharm S.A.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 2,361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 35
States / cities: Encino, California • Fullerton, California • La Mesa, California + 29 more

Search by objective public record fields.

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Feasibility of Early Gabapentin as an Intervention for Neurorecovery

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

Bupivacaine Pain Pumps to Decrease Mastectomy Post-Operative Pain

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Nitrite Infusion in High Risk Patients Undergoing Cardiopulmonary Bypass

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

A Study of Baricitinib (LY3009104) in Participants With COVID-19

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris